4 terminated, 4 unknown, 2 completed. 5 Phase 2, 4 Phase 1, 2 Early Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Unknown 3, Completed 1, Terminated 1 |
| Phase 1 | 4 | Terminated 2, Completed 1, Unknown 1 |
| Early Phase 1 | 2 | Terminated 1, Unknown 1 |
| Phase 3 | 1 | Unknown 1 |
Follow Angiotensin 1-7: new trials by email Literature Review of Angiotensin 1-7 trials Research Report on Angiotensin 1-7
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Biomarker Study: Heart Failure Patients at Risk Angiotensin 1-7, Saline solution - Heart Failure NYHA Class II, Heart Failure NYHA Class III | Phase 1 / Phase 2 | Unknown | University of Arizona | 40 | 2022-04-01 | 2022-04-20 |
| Angiotensin-(1,7) Treatment in COVID-19: the ATCO Trial Angiotensin 1-7, Placebos - Coronavirus, Respiratory Failure | Phase 2 / Phase 3 | Unknown | Erasme University Hospital | 60 | 2021-12-30 | 2021-08-02 |
| Angiotensin 1-7 as a Therapy in the Treatment of COVID-19 Angiotensin 1-7 - COVID-19 | Phase 2 | Unknown | Rambam Health Care Campus | 120 | 2021-01-18 | 2021-01-22 |
| Angiotensin-(1-7) in Peripheral Arterial Disease Angiotensin 1-7, Saline - Peripheral Arterial Disease | Early Phase 1 | Terminated | Milton S. Hershey Medical Center | 6 | 2017-09-01 | 2024-05-03 |
| Acute Effect of Agiotensin-(1-7) in Healthy and Hypertensive Subjects Angiotensin 1-7, Placebo - Hypertension | Early Phase 1 | Unknown | Instituto de Cardiologia do Rio Grande do Sul | 32 | 2014-01-01 | 2016-12-23 |
| Phase I Study Evaluating TXA127 in Low/Intermediate-1 Risk Myelodysplastic Syndrome and Thrombocytopenia TXA127 - Myelodysplastic Syndrome (MDS) | Phase 1 | Terminated | Tarix Pharmaceuticals | 2 | 2011-04-01 | 2016-08-31 |
| Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin, Non-Hodgkin Lymphoma or Multiple Myeloma Patients TXA127, Placebo - Lymphoma, Non-Hodgkin, Hodgkin Disease | Phase 2 | Terminated | Tarix Pharmaceuticals | 75 | 2010-06-01 | 2020-12-08 |
| Safety and Efficacy of TXA127 and Neupogen to Increase Peripheral Blood Stem Cells (PBSCs) TXA127, Neupogen (filgrastim) - Miscellaneous Peripheral Blood Cell Abnormalities | Phase 1 | Completed | Tarix Pharmaceuticals | 18 | 2009-12-01 | 2016-08-31 |
| Study of Drug to Reduce Thrombocytopenia in Patients Receiving Chemo for Ovarian, Fallopian Tube or Peritoneal Cancer TXA127, Placebo - Thrombocytopenia, Neutropenia | Phase 2 | Completed | Tarix Pharmaceuticals | 34 | 2008-10-01 | 2017-11-13 |
| Safety Study of TXA127 to Elevate CD4+ T-Lymphocyte Counts in HIV-Infected Patients on Stable HAART Therapy Angiotensin 1-7 - HIV Infections | Phase 1 | Terminated | US Biotest, Inc. | 13 | 2008-09-01 | 2012-02-29 |
Acquired Immunodeficiency Syndrome (1) · Anemia (1) · Atherosclerosis (1) · COVID-19 (1) · Coronavirus Infections (1) · Cytopenia (1) · HIV Infections (1) · Heart Failure (1) · Hodgkin Disease (1) · Hypertension (1) · Inflammation (1) · Lymphoma, Non-Hodgkin (1) · Lymphopenia (1) · Multiple Myeloma (1) · Myelodysplastic Syndromes (1)
Tarix Pharmaceuticals (4) · Erasme University Hospital (1) · Instituto de Cardiologia do Rio Grande do Sul (1) · Milton S. Hershey Medical Center (1) · Rambam Health Care Campus (1) · US Biotest, Inc. (1) · University of Arizona (1)
United States (7) · Israel (1)
Amy C Arnold, PhD (1) · Filippo Annoni, MD (1) · Lee Ryan, Ph.D. (1) · Michael Schuster, MD (1) · Robert A Larsen, MD (1) · Robson AS Santos, MD,PhD (1)